Compare Incyte Corporation (INCY) vs Newegg Commerce Inc (NEGG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Newegg Commerce Inc — how do they compare? Incyte Corporation trades at $118.01 (market cap $23.11B), while Newegg Commerce Inc trades at $13.71 (market cap $270.98M). The key difference: Incyte Corporation is far larger — about 85.3× Newegg Commerce Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Newegg Commerce Inc nearer its low. Which is the better fit depends on your goals.
| INCY | NEGG | |
|---|---|---|
Market Cap | $23.11B | $270.98M |
Sector | Health | Consumer Cyclical |
52-Week High | $118.52 | $128.09 |
52-Week Low | $67.38 | $12.92 |
Enterprise Value | $19.13B | $269.78M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
NEGG trades at $13.12, up 1.0% today, with a bearish technical outlook despite oversold RSI readings. The company shows improving fundamentals, with Q1 2026 EPS beating expectations and revenue stabilizing near $1.4B, though net margins remain thin at 0.39%. Recent news highlights product launches and AI shopping enhancements, signaling innovation efforts. Cash flow trends are volatile, with 2025 net cash flow positive at $8.91M but 2026 projecting a significant outflow.
The stock presents a mixed outlook: low P/S ratio of 0.19 suggests undervaluation relative to sales, but high P/E of 49.72 and consistent net losses pose risks. Analyst sentiment is bullish with a 100% buy rating, yet technical weakness and competitive e-commerce pressures require caution. Near-term catalysts include execution on profitability and AI initiatives, but investor patience is needed for sustained turnaround.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Newegg Commerce Inc
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products and provides certain third-party logistics services globally.
Read more on NEGG →
